The present invention relates to a new pharmaceutical composition of entacapone, levodopa and carbidopa or pharmaceutically acceptable or hydrates thereof characterized in that characterized in that it comprises a) a first granule wherein 90 % by weight of the total amount of levodopa is mixed with 90 % by weight of the total amount of carbidopa and 10% by weight of the total amount of entacapone, optionally in the presence of pharmaceutical acceptable excipients. b) a second granule wherein 10 % by weight of the total amount of levodopa is mixed with 10 % by weight of the total amount of carbidopa and 90% by weight of the total amount of entacapone, optionally in the presence of pharmaceutical acceptable excipients. c) Optionally mixed other pharmaceutically acceptable excipients, d) coating of core tablets is composed of hydroxypropyl cellulose and hydroxypropyl methyl cellulose.
